Eloralintide is investigational long-acting amylin receptor agonist (Eli Lilly; LY3841136). Eloralintide is an experimental once-weekly injection from Eli Lilly that mimics amylin, a hormone released with insulin that tells the brain you are full. It is being studied for weight management, alone and combined with tirzepatide.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Investigational: Phase 3 (ENLIGHTEN program); not approved. Source: Phase 3 obesity trial starts
Evidence tier: Phase 2 randomized trial; Phase 3 ongoing
Get alerts on legal status changes ->
What it is
Eloralintide is an experimental once-weekly injection from Eli Lilly that mimics amylin, a hormone released with insulin that tells the brain you are full. It is being studied for weight management, alone and combined with tirzepatide.
How it works
It selectively activates amylin receptors, which slow stomach emptying and increase fullness. It works through a different pathway from GLP-1 drugs.
What it's researched for
Obesity and overweight, type 2 diabetes, obstructive sleep apnea and knee osteoarthritis in people with obesity.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2024-02: Phase 2 trial starts (source)
- 2025-11: Phase 2 results published in The Lancet (48 weeks, mean weight loss up to about 20% vs 0.4% placebo) (source)
- 2025-12: ENLIGHTEN-2 Phase 3 starts (source)
- 2026-02: Phase 3 obesity trial starts (source)
Key trials and studies
- Phase 2, 48 weeks (Lancet 2025; NCT06230523)
- Phase 3 obesity (NCT07321886)
- ENLIGHTEN-2, with type 2 diabetes (NCT07282600)
- Phase 3 sleep apnea (NCT07369011)
- Phase 3 knee osteoarthritis (NCT07353931)
FAQ
Is eloralintide FDA approved?
No. As of Oct 29, 2026 eloralintide is in Phase 3 trials and is not approved.
What did the Phase 2 trial find?
In a 48-week Phase 2 trial of 263 adults, average weight loss reached about 20% in the upper treatment arms versus 0.4% on placebo. Nausea and fatigue were the most common side effects (Lancet, 2025).
How is eloralintide different from GLP-1 drugs?
It targets the amylin receptor, a separate fullness pathway, rather than the GLP-1 receptor.
Related peptides
- petrelintide FDA status and research
- cagrilintide FDA status and research
- pramlintide FDA status and research
- tirzepatide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Eloralintide or other peptides. Get alerts ->
Sources
- https://pubmed.ncbi.nlm.nih.gov/41207310
- https://clinicaltrials.gov/study/NCT07321886
- https://clinicaltrials.gov/study/NCT07282600
- https://clinicaltrials.gov/study/NCT07369011
- https://clinicaltrials.gov/study/NCT07353931
Editorial review - Last reviewed Oct 29, 2026